Luc J Farmer

6545049, Apr 8, 2003

Sep 2, 1999

09/388888

Chan K. Hwang - Boulder CO
Marcus F. Boehm - San Diego CA
Beth Ann Badea - San Diego CA
Laura J. Dardashti - Santa Anna CA
Lin Zhang - San Diego CA
Alex M. Nadzan - San Diego CA
Richard A. Heyman - Encinitas CA
Ranjan Mukherjee - San Diego CA
Deepak S. Lala - San Diego CA
Luc J. Farmer - La Jolla CA

Ligand Pharmaceuticals Incorporated - San Diego CA

A61K 3119

514569, 514725, 560500

Dimer-selective RXR modulator compounds having agonist, partial agonist and/or antagonist activity in the context of an RXR homodimer and/or RXR heterodimers are provided. Also provided are pharmaceutical compositions incorporating such dimer-selective RXR modulator compounds and methods for their therapeutic use.

6617309, Sep 9, 2003

Jun 6, 2001

09/875390

Roger D Tung - Beverly MA
Scott L. Harbeson - Cambridge MA
David D. Deininger - Arlington MA
Mark A. Murcko - Holliston MA
Govinda R. Bhisetti - Lexington MA
Luc J. Farmer - Foxborough MA

Vertex Pharmaceuticals Incorporated - Cambridge MA

A61K 31497

514 17, 514 18, 51425401, 530330, 544372

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.

6696459, Feb 24, 2004

Oct 14, 1997

08/950032

Todd K. Jones - Solana Beach CA
Mark E. Goldman - San Diego CA
Charlotte L. F. Pooley - San Diego CA
David T. Winn - San Diego CA
James P. Edwards - San Diego CA
Sarah J. West - San Diego CA
Christopher M. Tegley - San Diego CA
Lin Zhi - San Diego CA
Lawrence G. Hamann - San Diego CA
Luc J. Farmer - La Jolla CA
Robert L. Davis - Santee CA

Ligand Pharmaceuticals Inc. - San Diego CA

A61K 314353

514285, 514291, 514242, 514243, 51425501, 514256, 514259, 514267, 514292, 514299, 514300, 514301, 514302, 514303, 514314, 514312, 514311

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

6909000, Jun 21, 2005

Jul 11, 2002

10/193048

Luc J. Farmer - Foxborough MA, US
Janos Pitlik - Westborough MA, US
Robert B. Perni - Marlborough MA, US
Lawrence F. Courtney - Medway MA, US
John van Drie - Andover MA, US

Vertex Pharmaceuticals Incorporated - Cambridge MA

C07D241/10
C07D209/02
A61K031/4965
A61K031/40

544406, 5483121, 548452, 548515, 51425505, 514397, 514412, 514413

The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compounds of this invention have a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

6964973, Nov 15, 2005

Nov 18, 2002

10/299909

Lin Zhi - San Diego CA, US
Barbara Pio - San Diego CA, US
Luc Farmer - Foxborough MA, US

Ligand Pharmaceuticals Incorporated - San Diego CA

A61K031/4704
C07D215/227

514312, 514311, 514313, 546155, 546157, 546159, 546160, 546171, 546172, 546173

The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i. e. , partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis.

7241796, Jul 10, 2007

Oct 24, 2002

10/280940

Luc J. Farmer - Foxboro MA, US
Robert B. Perni - Marlborough MA, US
Janos Pitlik - Westborough MA, US
John H. van Drie, Jr. - Andover MA, US

Vertex Pharmaceuticals Inc. - Cambridge MA

A61K 31/40
A01N 43/38
C07D 209/56
C07D 487/00
C07D 491/00

514411, 514410, 514 19, 548424, 548429, 548430

The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

7273885, Sep 25, 2007

Apr 11, 2003

10/412600

Janos Pitlik - Westborough MA, US
Kevin M. Cottrell - Cambridge MA, US
Luc J. Farmer - Foxboro MA, US
Robert B. Perni - Marlborough MA, US
Lawrence F. Courtney - Medway MA, US
John H. van Drie - Andover MA, US
Mark A. Murcko - Holliston MA, US

Vertex Pharmaceuticals Incorporated - Cambridge MA

A61K 31/403
A61K 31/435
C07D 209/02
C07D 221/00

514414, 546 79, 546 85, 546112, 548134, 548146, 548182, 548225, 548250, 5482622, 548452, 548465, 514292, 514299

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

7276502, Oct 2, 2007

Mar 25, 2004

10/809946

Guy Brenchley - Grove Wantage, GB
Luc J. Farmer - Foxboro MA, US
Edmund M. Harrington - Plymouth MA, US
Ronald Knegtel - Abingdon, GB
Michael O'Donnell - Abingdon, GB
Francesco G. Salituro - Marlboro MA, US
John R. Studley - Abingdon, GB
Jian Wang - Newton MA, US

Vertex Pharmaceuticals Incorporated - Cambridge MA

C07D 417/04
A61K 31/506

5142358, 51425219, 514275, 544122, 544331

The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.